

City Health Information

Volume 42 (2023) | No 3; 32-48

New York City Department of Health and Mental Hygiene

INFLUENZA PREVENTION AND CONTROL, 2023-2024

- Provider recommendation is one of the greatest predictors of vaccination uptake.
 - Ensure that you and your entire staff receive the flu vaccine and counsel patients and caregivers on the benefits of flu vaccination.
- Use every opportunity to vaccinate all patients aged 6 months and older against influenza, especially those at risk of severe illness from influenza.
 - All routine vaccines can be coadministered with flu vaccines, including COVID-19 vaccines.
- Vaccinate all children aged 6 through 59 months attending City-licensed and City-regulated childcare against influenza by December 31st of each year, as vaccination is required for attendance by the New York City Health Code.
- Give inactivated flu vaccines to all pregnant persons in any trimester to prevent influenza infection and complications in the patient and infant.
- Administer high-dose, adjuvanted, or recombinant flu vaccines to patients aged 65 years and older.

INSIDE THIS ISSUE (click to access)

INTRODUCTION

- Important groups to vaccinate against influenza (box)
- Medical conditions that increase risk of severe complications from influenza (box)

VACCINATION COVERAGE AND INEQUITIES

STRONGLY RECOMMEND VACCINATION

- Common questions about the importance of flu vaccination (box)
- What to tell patients about flu vaccine safety (box)
- Immunization and pharmacists (box)

ENSURE YOU AND YOUR STAFF ARE VACCINATED

- Vaccination requirements for health care workers (box)

IMPROVE VACCINATION COVERAGE

- Key standards for adult immunization practice (box)

VACCINATE CHILDREN AS EARLY AS POSSIBLE

VACCINATE PREGNANT PATIENTS

- Reasons to give the flu vaccine in any trimester of pregnancy (box)

VACCINATE OLDER ADULTS

TIMING OF FLU VACCINES

THIS SEASON'S VACCINES

- Available flu vaccines for the 2023-2024 season (table)

ASSESS FOR CONTRAINDICATIONS AND PRECAUTIONS

- Contraindications and precautions for persons with previous severe allergic reaction to flu vaccine (table)

PROTECT AGAINST OTHER RESPIRATORY INFECTIONS AND THEIR COMPLICATIONS

- Pneumococcal vaccine administration for adults who have never received pneumococcal conjugate vaccine (table)

PRESCRIBE ANTIVIRALS FOR TREATMENT AND PROPHYLAXIS

- High-risk groups who should receive antiviral treatment for influenza (box)

REPORTING, ALERTS, AND SURVEILLANCE

SUMMARY

- Flu vaccine reminders (box)

RESOURCES FOR PROVIDERS

RESOURCES FOR PATIENTS

REFERENCES

CONTINUING MEDICAL EDUCATION ACTIVITY (1 CREDIT)

Influenza is a highly contagious viral infection that results in serious illnesses, hospitalizations, and deaths every season. Infants, pregnant persons, older adults, and people of any age with certain medical conditions are at higher risk of serious complications.¹

During the 2022-2023 season, influenza activity in New York City (NYC) and both influenza activity and hospitalizations in the United States (US) overall were higher than in recent years; activity peaked early in the season locally and nationally.¹ There were 7 influenza-associated deaths among children in New York City (NYC) in the 2022-2023 season; in the US, 176 children died of influenza.^{2,3}



Vaccination is our best defense against influenza and its complications. An estimated 1.8 million influenza cases, 22,000 hospitalizations, and nearly 1,000 deaths were prevented by vaccination in the US during the 2021-2022 influenza season.⁴ The largest proportions of these negative outcomes were estimated to have been prevented among children aged 6 months to 4 years, who received flu vaccination at a moderate rate (67%) and for whom vaccine effectiveness was greatest (77%).⁴

In the US, influenza viruses circulate most commonly from late fall through early spring, though the timing, intensity, and severity of each season cannot be predicted.¹ SARS-CoV-2 will continue to cocirculate with influenza, and relaxation of COVID-19 mitigation measures could result in increased activity for both viruses.⁵ Flu vaccination will reduce the overall burden of influenza-related illnesses and protect people at risk of severe influenza-related illness. Use every opportunity to administer flu vaccines to all persons aged 6 months and older. Ensure those at greatest risk of severe illness from influenza are vaccinated (**Boxes 1^{1,6}** and **2^{1,6}**).

VACCINATION COVERAGE AND INEQUITIES

Despite the importance of flu vaccination, coverage in NYC fell short of the Healthy People 2030 target of 70.0%⁷ for most age groups in recent years.

Among NYC residents, flu vaccination coverage among children aged 18 years and younger was lower in the 2022-2023 season than in the prior season; it was 42.5% overall, 57.2% for children aged 6 through 59 months, 39.9% for children aged 5 through 8 years, and 36.6% for children aged 9 through 18 years (unpublished data, Citywide Immunization Registry [CIR]). In the 2019-2020 season, coverage among children aged 6 through 59 months was greater (65.9%; unpublished data, CIR) and had increased each season since the NYC Health Code requirement that children in City-licensed and City-regulated childcare be vaccinated against influenza was reinstated in 2018.⁸ However, during the 2022-2023 season, there was a 9% decrease in vaccination coverage for children in this age group compared with the 2019-2020 season. Disruption in childcare attendance and routine immunization services during the COVID-19 pandemic has likely contributed to the lower coverage.

In 2022, 51.4% of adults aged 18 years and older reported receiving the flu vaccine in the past 12 months (unpublished data, 2022 Community Health Survey). There were substantial inequities in vaccination by race and ethnicity. Compared with nonLatino White adults, adults who

BOX 1. IMPORTANT GROUPS TO VACCINATE AGAINST INFLUENZA^{1,6}

- All children aged 6 through 59 months, especially those aged younger than 2 years
- Adults aged 50 years and older, especially those aged 65 years and older
- People who are or may be pregnant during influenza season
- Residents of nursing homes and other long-term care facilities
- Adults and children with certain high-risk medical conditions (**Box 2**)
- Health care workers
- Household contacts and caregivers of
 - children aged younger than 5 years, especially those younger than 6 months
 - adults aged 50 years and older
 - people with certain medical conditions (**Box 2**)
- NonLatino Black, Latino, and American Indian or Alaska Native people^a
- People at [increased risk](#) of severe COVID-19

^aRisk is due to [structural racism](#) and health care access; see [Health Equity and Flu](#)

BOX 2. MEDICAL CONDITIONS THAT INCREASE RISK OF SEVERE COMPLICATIONS FROM INFLUENZA^{1,6}

- Asthma or chronic lung disease (eg, chronic obstructive pulmonary disease, cystic fibrosis)
- Heart disease (eg, congenital heart disease, congestive heart failure, coronary artery disease) or stroke
- Renal, hepatic, neurologic, hematologic, or metabolic disorders, including diabetes
- Immunocompromise due to any cause, including immunosuppression caused by medications or by HIV infection
- Conditions requiring use of aspirin- or salicylate-containing medications in people aged younger than 19 years because of risk of Reye syndrome after influenza infection
- Morbid obesity (body mass index ≥ 40)

The New York City Health Code requires all children aged 6 through 59 months attending City-licensed and City-regulated day care, school-based childcare, Head Start, and prekindergarten programs to receive an annual flu vaccine by December 31st of each year.

identify as nonLatino Black, Latino, and nonLatino Other Race received flu vaccines at lower rates (55.2% vs 42.0%, 48.4%, and 45.1%, respectively). Flu vaccine coverage among nonLatino Asian/Pacific Islander adults (62.9%) was higher than nonLatino White adults. Among adults aged 65 years and older, 72.4% reported that they received the flu vaccine in the past 12 months. Compared with nonLatino White adults, older adults who identify as nonLatino Black received flu vaccine at lower rates (74.8% vs 64.6%), but there was no significant difference in flu vaccine coverage among Latino or nonLatino Asian/Pacific Islander older adults compared with nonLatino White older adults (70.5%, 78.7%, and 74.8%, respectively) (unpublished data, 2022 Community Health Survey).

Lack of access to health care and low confidence in vaccines affect vaccination uptake among people across racial, ethnic, religious, and other groups. Unethical medical research and practices in the past, along with ongoing structural racism and discrimination in health care, have created a long-standing mistrust in medical research, health care institutions, medical providers, and vaccines among many people, including Black, Indigenous, and people of color (BIPOC).⁹⁻¹⁷ Although demographic statistics are commonly used to highlight health inequities, race and ethnicity are social constructs,¹⁸ not biological ones; there are no physiologic differences in disease processes by race. However, structural and interpersonal racism do influence the distribution of

social, economic, and environmental conditions needed for health. The NYC Board of Health has declared racism a [public health crisis](#).

Learn more at [Racism and Health](#) and [Health Equity and Flu](#), and about building your patients' trust in your health care practice at [Conversations to Build Trust in Vaccination: A Training Module for Health Workers](#).

STRONGLY RECOMMEND VACCINATION

A strong recommendation from a health care provider is one of the greatest predictors of a patient getting vaccinated.^{19,20} Build confidence in the safety and effectiveness of flu and other vaccines with discussion at every visit, especially among patients who are BIPOC (**Resources**).²¹

- Listen with empathy, and respectfully address questions or concerns that keep the patient or parent from readily accepting vaccination (**Boxes 3**^{1,22,23} and **4**^{1,22,24-27}).
- Share why you, your staff, and your family get vaccinated against influenza each year.
- Ensure that all staff who have contact with patients give the same culturally competent, affirmative, and accurate messages about flu vaccination (**Resources**).
 - As required by law, before vaccinating, give patients the Centers for Disease Control and Prevention (CDC) Vaccine Information Statement (VIS), which explains the benefits and risks of a vaccine. VISs are available in more than 40 languages at [Immunize.org](#); provide one in a language

BOX 3. COMMON QUESTIONS ABOUT THE IMPORTANCE OF FLU VACCINATION^{1,22,23}

Q: Why do I need a flu vaccine?

A: You need a flu vaccine because influenza can cause severe illness, especially in young children, pregnant people, older adults, and people with certain medical conditions such as asthma, heart disease, and diabetes. Influenza can cause complications that lead to hospitalization and death, even in healthy children and adults.

Q: Will a flu vaccine do any good? I got a flu vaccine once and got the flu anyway.

A: Yes, a flu vaccine will give you protection against the influenza virus and prevent many influenza infections, even though it may not be 100% effective. If you do get influenza, the vaccine can make your illness milder and reduce the risk of complications, including hospitalization and death.

Q: How late is too late to get a flu vaccine?

A: You can be vaccinated against influenza at any time during influenza season. Influenza viruses circulate all year. Influenza activity is usually highest between December and March, but there have been high numbers of cases as late as May. While we recommend getting the vaccine at the start of the season, you should still get vaccinated in the winter or spring if you were not vaccinated earlier.

Q: Do I need a flu vaccine every year?

A: Yes, everyone aged 6 months and older needs a flu vaccine every year, since influenza viruses can change each influenza season. This year's flu vaccine includes 1 new influenza strain.

Q: Why do I need a flu vaccine if other people are vaccinated? Won't that keep me from getting influenza?

A: Your best protection against influenza is getting vaccinated yourself. Influenza is very contagious. People who do not get vaccinated can get influenza and pass it on to people who may be more likely to have serious complications, including infants, pregnant people, older adults, and people with certain health conditions.

that the recipient or parent best understands.

- Share clear information from trusted sources and be transparent about what you do and do not know.
- Recognize that all people across racial, ethnic, religious, and other groups can experience low vaccine confidence and that the reasons behind their uncertainties are not uniform across any group.
- Understand that perceived unfair treatment by a provider can discourage patient vaccination.¹⁵

BOX 4. WHAT TO TELL PATIENTS ABOUT FLU VACCINE SAFETY^{1,22,24-27}

Vaccines generally cause only mild reactions

- Most side effects are minor and pass quickly; serious side effects are rare
 - The flu shot can cause soreness, redness, or swelling at the injection site, headache, fatigue, muscle aches, and low-grade fever
 - The nasal spray flu vaccine may cause a reaction in the nose, such as nasal congestion
- Flu vaccines have a long safety track record and are thoroughly tested by the United States Food and Drug Administration (FDA)
 - The FDA and Centers for Disease Control and Prevention maintain robust surveillance systems to detect and identify any safety issues

The flu vaccine is made from safe ingredients

- Thimerosal is a vaccine preservative made with ethyl mercury. Ethyl mercury is not the same as the type of mercury associated with fish (which is called methylmercury). Ethyl mercury is quickly eliminated by your body and does not cause harm
- **No adverse health effects** have been found with the low doses of thimerosal in vaccines; there have been minor reactions such as redness and swelling at the injection site
 - There is no thimerosal in single-dose preparations of the flu vaccine; all multidose vials of the flu vaccine contain a small amount of thimerosal

The flu vaccine is unlikely to cause a severe allergic reaction

- Many forms of the flu vaccine **do not contain** common allergens such as preservatives, antibiotics, or gelatin; some are egg-free. There is no latex in any of this season's vaccines
- Your allergies will be reviewed to assess whether you are eligible to receive the flu vaccine

The flu vaccine cannot cause influenza

- The inactivated flu vaccine does not contain live viruses, so it cannot cause influenza
- The nasal spray flu vaccine does contain live viruses; however, the viruses are weakened so that they cannot cause influenza, but they may cause nasal congestion

- Advise patients that flu vaccination is covered by most insurance plans and is available at no cost (under the Affordable Care Act), though there may be a copayment for office visits and restrictions on out-of-network providers.
 - For practices and facilities that see children, **enroll in the Vaccines for Children (VFC) program**. VFC provides vaccine at no cost to the provider to vaccinate eligible children (eg, those with public health insurance and those who are uninsured).
 - For providers enrolled in the VFC program, maintain sufficient supplies of VFC vaccine. More children may have become eligible for the VFC program because of insurance loss or economic hardship due to the COVID-19 pandemic. In NYC, 75% of children are estimated to be eligible to receive vaccine through the VFC program (unpublished data, 2023 CDC Population Estimate Survey).
- If you do not offer vaccinations, refer patients to other vaccine providers, including pharmacies (**Box 5**²⁸⁻³⁰).

BOX 5. IMMUNIZATION AND PHARMACISTS²⁸⁻³⁰

- Pharmacists in New York State are currently authorized to administer
 - Flu vaccines to everyone aged 2 years and older
 - COVID-19 vaccines to everyone aged 3 years and older
 - Respiratory syncytial virus, tetanus, diphtheria, pertussis, pneumococcal, meningococcal, zoster, hepatitis A, hepatitis B, human papillomavirus, measles, mumps, rubella, and varicella vaccines to adults aged 18 years and older
 - Additional vaccines recommended by the Advisory Committee on Immunization Practices may be authorized by the New York State Commissioner of Health
- Patients can check with their local pharmacy directly or visit NYC **Vaccine Finder** and **HealthMap** to search for available vaccines, ages served,^a and payment and insurance information
- Pharmacists administering flu vaccines should check the **Citywide Immunization Registry (CIR)** to assess for and coadminister any other vaccines that are due
- Pharmacies routinely report flu and other vaccinations to the CIR; during the 2022-2023 season, they reported administering almost 820,000 doses of the flu vaccine (unpublished data, CIR)

^aNew York State pharmacists may vaccinate children aged as young as 2 years, but each pharmacy may have its own age limits

ENSURE YOU AND YOUR STAFF ARE VACCINATED

All health care workers should be vaccinated against influenza as soon as vaccine is available to protect themselves, their families, and their patients from influenza infection and transmission (**Box 6**³¹).

IMPROVE VACCINATION COVERAGE

During the COVID-19 pandemic, there was a substantial disruption in the administration of routine vaccines in NYC, including among children.³² In addition to assessing vaccination status and strongly recommending all due or overdue vaccines at every visit, implement best practices, such as using standing orders, reminder-recall systems, self-screening tools, posters, and patient handouts to improve vaccination uptake and reduce inequities (**Resources**). Follow the National Vaccine Advisory Committee (NVAC) [Standards for Adult Immunization Practice](#) (**Box 7**^{33,34}) and [Standards for Child and Adolescent Immunization Practices](#).

Key standards for child and adolescent immunization practices include³⁵:

- Ensuring vaccination services are readily available, coordinated with other health care providers, and provided in a medical home when possible;
- Identifying and minimizing barriers to vaccination;
- Minimizing patient costs;
- Reviewing the vaccination and health status of patients at every encounter to determine which vaccines are indicated;
- Assessing for and following only medically accepted contraindications;
- Simultaneously administering as many indicated vaccine doses as possible;
- Using systems to remind parents/guardians, patients, and health care professionals when vaccinations are due and overdue;
- Performing office- or clinic-based patient record reviews and vaccination coverage assessments annually.

VACCINATE CHILDREN AS EARLY AS POSSIBLE

Young children are at high risk of serious complications from influenza.¹ It is especially important to protect infants aged younger than 6 months from being exposed to influenza because

they are at high risk of influenza-related hospitalizations and medically attended visits but are too young to be vaccinated. The best way to protect an infant is to vaccinate the parent when pregnant. Strongly encourage childcare providers and members of households with young children to get vaccinated.

BOX 6. VACCINATION REQUIREMENTS FOR HEALTH CARE WORKERS³¹

- When the New York State Commissioner of Health declares that influenza is prevalent, Articles 28, 36, and 40 require health care and residential facilities to
 - document the flu vaccination status of all health care workers
 - provide masks for unvaccinated workers and ensure that masks are worn in the presence of patients or residents as long as influenza is prevalent
- Many health care facilities must also report health care workers' vaccination status to the Centers for Medicare and Medicaid Services (CMS) using the National Healthcare Safety Network platform. See [CMS Requirements](#)

BOX 7. KEY STANDARDS FOR ADULT IMMUNIZATION PRACTICE^{33,34}

1. **ASSESS the immunization status of all patients at every visit**
2. **STRONGLY RECOMMEND needed vaccines**
3. **ADMINISTER needed vaccines or REFER patients to another vaccinator**
 - Administer all due or overdue vaccinations according to the routine [immunization schedule](#) during the same visit. All routine vaccines can be coadministered with flu vaccines, including COVID-19 vaccines
 - Use nonpatient-specific [standing orders](#) to allow registered nurses to independently assess patient vaccination status and administer needed vaccines without a direct order from the physician; this will save time and reduce missed opportunities for vaccination (**Resources**)
 - If you do not stock vaccine, use NYC [Vaccine Finder](#) and [HealthMap](#) to refer patients to a local vaccine provider, such as a pharmacist (**Box 5**, page 35)
4. **DOCUMENT all vaccines that patients receive**
 - Use the [Citywide Immunization Registry](#) (CIR) to document vaccinations and to let other providers know which vaccines patients have received
 - Providers must report all immunizations administered to persons aged 18 and younger
 - Providers should report all immunizations administered to persons aged 19 years and older to the CIR, with the patient's written or oral consent
 - Encourage patients to consent by discussing the advantages of reporting, such as online access to vaccine records

The CDC recommends administering 2 doses of the flu vaccine (at least 4 weeks apart) to all children aged 6 months through 8 years if they have not received 2 or more doses of the flu vaccine before July 1, 2023.¹ For children who received 2 doses of the flu vaccine before July 1, 2023, the 2 doses of the flu vaccine need not have been administered in the same season or in consecutive seasons. Children aged 8 years or younger who have received 2 doses before July 1, 2023, and children older than age 8 years should receive 1 dose of the flu vaccine. Pharmacists in NYS can administer flu vaccines to children aged 2 years and older (**Box 5**, page 35).

VACCINATE PREGNANT PATIENTS

Influenza can be dangerous to pregnant people and infants who are too young to receive the vaccine. The flu vaccine protects pregnant people against influenza, as well as their newborns in the first few months of life, through transplacental transfer of antibodies during pregnancy.³⁶ The American College of Obstetricians and Gynecologists (ACOG)³⁷ and the Advisory Committee on Immunization Practices (ACIP)¹ recommend that all people who are or will be pregnant receive an annual inactivated influenza vaccine. In 2021, nearly 1 in 5 pregnant people in NYC reported that they did not get a recommendation from their health care provider to receive a flu vaccine during the 12 months before delivery; only 56.3% of pregnant people reported receiving the flu vaccine that year (unpublished data, Pregnancy Risk Assessment Monitoring System [PRAMS]).

Provider recommendation is one of the greatest predictors of vaccination.^{19,20} Strongly recommend and offer inactivated flu vaccines to all pregnant people (**Box 8**^{1,27,36-41}). Pregnant people in their third trimester of pregnancy should be offered vaccine as soon as it becomes available.¹

VACCINATE OLDER ADULTS

For adults aged 65 years and older, ACIP recommends high-dose, adjuvanted, or recombinant flu vaccines preferentially, as there is evidence of greater potential benefit with these vaccines for older adults.¹ If high-dose, adjuvanted, or recombinant flu vaccines are not available at an opportunity for vaccine administration, use any other age-appropriate influenza vaccine.¹

TIMING OF FLU VACCINES

In the US, the composition of flu vaccines is determined in February or March of each year

for the upcoming flu season based on a variety of factors, including epidemiologic, genetic, and antigenic data, evolutionary analysis, and human serology and vaccine effectiveness studies.^{1,42} Flu vaccines may be available as soon as July or August each year.

Vaccinate children who require 2 doses of the flu vaccine with their first dose as soon as vaccine becomes available so the second dose can be given by the end of October.¹ Vaccinate children who require only one dose of vaccine as soon as vaccine is available; there is less evidence that immunity wanes over time among children as compared with adults.¹ Similarly, vaccinate pregnant persons in their third trimester soon after vaccine becomes available to reduce their infants' risk of flu during the first months of life.¹ However, for most adults (particularly adults aged ≥ 65 years) and for pregnant persons in the first or second trimester, avoid flu vaccination in July and August unless later vaccination may not be possible, since the vaccine may be less effective before the end of influenza season, especially among older adults.¹

THIS SEASON'S VACCINES

For the 2023-2024 season, all influenza vaccines are only available in quadrivalent formulation.¹ All US-licensed influenza vaccines will include hemagglutinin derived from an:

- Influenza A/Victoria/4897/2022 (H1N1) pdm09-like virus (egg-based vaccines),
- Influenza A/Wisconsin/67/2022 (H1N1) pdm09-like virus (cell and recombinant vaccines),

BOX 8. REASONS TO GIVE THE FLU VACCINE IN ANY TRIMESTER OF PREGNANCY^{1,27,36-41}

- Pregnant people are 7 times more likely to have an influenza-related hospitalization than nonpregnant people
- Influenza increases the risk of premature labor and delivery
- Vaccination prevents influenza infection in the infant through transplacental antibody transfer, which protects infants aged younger than 6 months who are too young to get vaccinated and at high risk of complications
- Vaccination with inactivated vaccine during pregnancy is safe in any trimester
- Inactivated flu vaccines have been given to millions of pregnant people without harm and are available in single-dose preparations without thimerosal

- Influenza A/Darwin/9/2021 (H3N2)-like virus (egg-based vaccines),
- Influenza A/Darwin/6/2021 (H3N2)-like virus (cell and recombinant vaccines),
- Influenza B/Austria/1359417/2021-like virus (B/Victoria lineage),
- Influenza B/Phuket/3073/2013-like virus (B/Yamagata lineage).

In all flu vaccines (IIV4, LAIV4, ccIIV4, RIV4), the influenza A (H1N1)pdm09 components were updated from last season's formulations to better match circulating strains. Administer any licensed, age-appropriate influenza vaccine.¹ See **Table 1¹** for information on this season's vaccines.

ASSESS FOR CONTRAINDICATIONS AND PRECAUTIONS

Ask about patients' current health status, including any acute illness and history of reactions

to flu vaccines. Alert patients to potential reactions to the vaccine and tell them to report any concerning reactions.

Of note, for people with egg allergies, the CDC no longer recommends additional safety precautions for flu vaccination beyond those recommended for any recipient of any vaccine, regardless of severity of previous reaction to egg.¹ Any flu vaccine (egg based or nonegg based) that is otherwise appropriate for the person's age and health status can be used. The CDC's recommendations align with those of the American Academy of Pediatrics, American Academy of Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and Immunology.

- Current illness: A patient with mild illness, such as diarrhea, upper respiratory tract illness, or otitis media, or on current antimicrobial therapy can be safely vaccinated.⁴³ If illness is moderate to severe, with or with-

TABLE 1. AVAILABLE FLU VACCINES FOR THE 2023-2024 SEASON^{a,1}

Type	Trade Name	Manufacturer	Age Indication	Presentation	Thimerosal Content ^b
IIV4	Afluria Quadrivalent	Seqirus	≥3 y ^c	0.5-mL prefilled syringe ^c	Preservative-free
			≥6 mos ^{c,d}	5.0-mL multidose vial ^c	24.5 mcg/0.5mL
	Fluarix Quadrivalent	GlaxoSmithKline	≥6 mos	0.5-mL prefilled syringe	Preservative-free
	FluLaval Quadrivalent	GlaxoSmithKline	≥6 mos	0.5-mL prefilled syringe	Preservative-free
	Fluzone Quadrivalent	Sanofi Pasteur	≥6 mos ^e	0.5-mL prefilled syringe ^e	Preservative-free
				0.5-mL single-dose vial ^e	Preservative-free
				5.0-mL multidose vial ^e	25 mcg/0.5mL
ccIIV4	Flucelvax Quadrivalent	Seqirus	≥6 mos	0.5-mL prefilled syringe	Preservative-free
				5.0-mL multidose vial	25 mcg/0.5mL
High-dose IIV4	Fluzone High-Dose Quadrivalent	Sanofi Pasteur	≥65 y	0.7-mL prefilled syringe	Preservative-free
Adjuvanted IIV4	Fluad Quadrivalent	Seqirus	≥65 y	0.5-mL prefilled syringe	Preservative-free
RIV4	Flublok Quadrivalent	Sanofi Pasteur	≥18 y	0.5-mL prefilled syringe	Preservative-free
LAIV4	FluMist Quadrivalent	AstraZeneca	2-49 y	0.2-mL single-dose prefilled intranasal sprayer	Preservative-free

ccIIV4, cell culture-based inactivated influenza vaccine, quadrivalent; IIV4, inactivated influenza vaccine, quadrivalent; LAIV4, live attenuated influenza vaccine, quadrivalent; RIV4, recombinant influenza vaccine, quadrivalent

^aAll vaccines listed are intramuscular, except LAIV4, which is intranasal; all vaccines listed are latex-free

^bNew York State law prohibits the administration of vaccines containing more than trace amounts of thimerosal to pregnant people and children aged younger than 3 y, unless vaccine that complies with the law cannot be obtained despite good-faith effort. In these instances, vaccination of children aged younger than 3 y and pregnant people is still recommended because the substantial risk of complications or death from influenza in these groups outweighs the unproven risk of vaccination with thimerosal-containing vaccine

^cThe approved dose volume for Afluria Quadrivalent is 0.25 mL for children aged 6 through 35 months and 0.5 mL for persons aged ≥3 years. However, 0.25-mL prefilled syringes are no longer available. For children aged 6 through 35 months, a 0.25-mL dose must be obtained from a multidose vial.

^dMay be given by jet injector instead of needle and syringe for persons aged 18 through 64 years only

^eFluzone Quadrivalent is approved for children aged 6 through 35 months at either 0.25 mL or 0.5 mL per dose; however, 0.25-mL prefilled syringes are no longer available. If a prefilled syringe of Fluzone Quadrivalent is used for a child in this age group, the dose volume will be 0.5 mL per dose.

- out fever, consider the risks and benefits of administering the flu vaccine.⁴³
- History of Guillain-Barré Syndrome (GBS): Explain the risks and benefits of vaccination in patients with a history of GBS within 6 weeks of receipt of a previous flu vaccination.⁴³ If such patients are also at high risk of severe influenza complications, the benefits may outweigh the risks.¹
 - A previous severe allergic reaction to the flu vaccine, such as anaphylaxis, may be a precaution for, or contraindication to, future receipt of the vaccine.¹ See **Table 2¹** for details.
 - A previous severe allergic reaction to any component of a specific flu vaccine is a contraindication to receipt of that vaccine.¹
 - Although a history of severe allergic reaction (eg, anaphylaxis) to egg is a labeled contraindication to the use of egg-based IIV4s and LAIV4, the CDC recommends that all persons aged 6 months and older with egg allergy should receive influenza vaccine and that any influenza vaccine (egg based or nonegg based) that is otherwise appropriate for the recipient’s age and health status can be used.

Inform patients that alternate formulations of the flu vaccine are available if they have a known allergy to one or more vaccine components, including preservatives, antibiotics, or gelatin. None of the 2023-2024 vaccines contain latex. Check the [CDC Vaccine Excipient Table](#) or vaccine package inserts to find a formulation without the implicated ingredient.

ACIP recommends that LAIV should not be administered to the following groups¹:

- Children and adolescents taking concomitant aspirin or salicylate-containing medications;

- Children aged 2 through 4 years who have received a diagnosis of asthma or whose parents report (or medical record notes) that the child had wheezing or asthma during the preceding 12 months;
- People who are immunocompromised due to any cause;
- People with
 - a cochlear implant,
 - an active cerebrospinal fluid leak;
- Close contacts and caregivers of persons with severe immunosuppression who require a protected environment;
- Pregnant people;
- Persons who have taken influenza antiviral medications within the previous 48 hours to 17 days, depending on the antiviral used.

Precautions to LAIV use include asthma in persons aged 5 years and older and the presence of certain medical conditions that might predispose to complications after wild-type influenza infection (eg, chronic pulmonary, cardiovascular [except isolated hypertension], renal, hepatic, neurologic, hematologic, or metabolic disorders [including diabetes]).¹ When a precaution is present, vaccination should generally be deferred, but may be indicated if the benefit of protection from the vaccine outweighs the risk of an adverse reaction.

PROTECT AGAINST OTHER
RESPIRATORY INFECTIONS AND THEIR
COMPLICATIONS

COVID-19

Administer COVID-19 vaccines with flu and other vaccines. The updated 2023-2024 formula of COVID-19 vaccines are monovalent vaccines targeting the Omicron variant XBB.1.15. In

TABLE 2. CONTRAINDICATIONS AND PRECAUTIONS FOR PERSONS WITH PREVIOUS SEVERE ALLERGIC REACTION TO FLU VACCINE¹

Flu vaccine ^a associated with previous severe allergic reaction (eg, anaphylaxis)	Egg-based IIV4 and LAIV4	ccIIV4	RIV4
Any egg-based IIV or LAIV	Contraindication ^b	Precaution ^c	Precaution ^c
Any ccIIV	Contraindication ^b	Contraindication ^b	Precaution ^c
Any RIV	Contraindication ^b	Precaution ^c	Contraindication ^b
Unknown	Consult with allergist		

ccIIV, cell culture-based inactivated influenza vaccine; IIV, inactivated influenza vaccine; LAIV, live attenuated influenza vaccine; RIV, recombinant influenza vaccine

^aAny valency
^bDo not administer vaccine
^cVaccination should be deferred but may be indicated if the benefit of protection from the vaccine outweighs the risk of an adverse reaction

September 2023, the US Food and Drug Administration (FDA) approved and authorized two mRNA COVID-19 vaccines for use in people aged 6 months and older.⁴⁴ The CDC has [recommended](#) the updated vaccines using a simplified vaccination schedule; most individuals, with the exception of very young children and those with moderate to severe immunocompromise, will be up to date when they receive one dose of the updated vaccine, regardless of the previous doses they have received and even if they never received a COVID-19 vaccine. People aged 6 months through 4 years or who are moderately to severely immunocompromised should receive a multi-dose initial series, with at least one dose being the updated 2023–2024 COVID-19 vaccine. Bivalent mRNA vaccines are no longer authorized for use in the US. See [Interim Clinical Considerations](#) and [COVID-19 Vaccine Information for Providers](#) for up-to-date information on COVID-19 vaccines, including vaccine schedules, special populations, and contraindications.

Advise patients that COVID-19 vaccination is available at no cost (under the Affordable Care Act) through most private insurance plans, Medicare, and Medicaid; at no cost for children eligible for the VFC program; and at no cost for uninsured and underinsured adults through the NYC Vaccines for Adults program, also known as the Bridge Access Program for COVID-19 Vaccines. The NYC [Vaccine Finder](#) provides locations where adults who are uninsured or underinsured can receive no-cost COVID-19 vaccination.

Email nycimmunize@health.nyc.gov to enroll in the VFC Program or learn about no-cost COVID-19 vaccines for uninsured and underinsured adults.

Pneumococcal disease

Pneumococcal infection is a serious complication of influenza that can lead to severe pneumonia, meningitis, bacteremia, and sinus and ear infections.⁴⁵ Four vaccines are approved to prevent pneumococcal disease: 3 pneumococcal conjugate vaccines (PCV13, PCV15, and PCV20) and 1 pneumococcal polysaccharide vaccine (PPSV23).⁴⁶

Per updated [ACIP recommendations](#), children aged 59 months and younger should routinely receive the PCV13, PCV15, or PCV20 series.⁴⁶ Some children with chronic medical conditions should receive additional doses and/or PPSV23, depending on previous vaccination history and specific medical condition present. PCV13 is expected to

be removed from market after a transition period.⁴⁷

ACIP recommendations for pneumococcal vaccination in adults were revised.⁴⁶ Adults aged 65 years and older who have not received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown should routinely receive either PCV20 alone or PCV15 followed by PPSV23 (**Table 3⁴⁸**). Individuals aged 65 years and older who previously received PCV13 should receive either PCV20 or PPSV23, and those who previously received PPSV23 should receive PCV20 or PCV15 alone. For adults aged 19 through 64 years with a qualifying medical condition who have not received any pneumococcal vaccine or whose previous vaccination history is unknown, administer PCV20 alone or PCV15 followed by PPSV23 (**Table 3**). Adults aged 19 to 64 years with a qualifying medical condition and who previously received an incomplete pneumococcal series will require additional pneumococcal vaccines depending on vaccine history and the qualifying medical condition present.

See [Pneumococcal ACIP Vaccine Recommendations; Pneumococcal Vaccination: Summary of Who and When to Vaccinate](#); and [Pneumococcal Vaccine Timing for Adults](#) for detailed guidance.

The Centers for Medicare and Medicaid Services covers the cost of pneumococcal vaccination for Medicare patients, in accordance with current ACIP recommendations.

Respiratory syncytial virus infection

The FDA has approved 2 respiratory syncytial virus (RSV) vaccines for use in adults aged 60 years and older. The CDC recommends that adults aged 60 years and older may receive a single dose of RSV vaccine, after shared clinical decision-making with their healthcare provider.⁴⁹ As part of this discussion, providers and patients should consider the patient's risk of severe RSV-associated disease, such as the presence of chronic underlying medical conditions or other factors associated with increased risk (eg, frailty, advanced age, or residence in a nursing home or other long-term care facility).⁴⁹ Although there are currently limited data available on immunogenicity of coadministration of adult RSV vaccines and other vaccines, the CDC considers coadministration of RSV vaccines with other adult vaccines during the same visit acceptable.

In August 2023, the FDA approved an RSV vac-

cine for use in pregnant people between week 32 and week 36 of gestation to prevent RSV-related lower respiratory tract disease in infants from birth through age 6 months.⁵⁰ To maximize protection for infants, the CDC recommends seasonal administration of one dose of RSV vaccine for pregnant people during weeks 32 through 36 of pregnancy.⁵¹

The FDA has also approved the monoclonal antibody nirsevimab for the prevention of RSV-associated lower respiratory tract disease in neonates and infants.⁵² The CDC recommends nirsevimab for use in infants aged less than 8 months who are born in or entering their first RSV season, and for children aged 8 to 19 months who are at in-

creased risk of RSV disease entering their second RSV season.⁵²

Pertussis

When offering and administering flu vaccines, providers should also strongly recommend and offer tetanus, diphtheria, and pertussis (Tdap) vaccine to all pregnant people during each pregnancy, preferably during 27 to 36 weeks' gestation. Young infants are at greatest risk of severe disease, hospitalization, and death from pertussis.⁵³ Like the flu vaccine, the Tdap vaccine protects newborns in the first few months of life against pertussis through transplacental transfer of antibodies during pregnancy. A large US study

TABLE 3. PNEUMOCOCCAL VACCINE ADMINISTRATION FOR ADULTS WHO HAVE NEVER RECEIVED PNEUMOCOCCAL CONJUGATE VACCINE⁴⁸

Underlying Medical Condition or Other Risk Factors	Ages 19 Through 64 y	Ages ≥65 y
None	Not recommended	Administer 1 dose of PCV20 OR 1 dose of PCV15 followed by 1 dose of PPSV23 at least 1 year later
Alcoholism	Administer 1 dose of PCV20 OR 1 dose of PCV15 followed by 1 dose of PPSV23 at least 1 year later <i>The minimum interval (8 weeks) can be considered for adults with an immunocompromising condition, cochlear implant, or cerebrospinal fluid leak.</i>	Administer 1 dose of PCV20 OR 1 dose of PCV15 followed by 1 dose of PPSV23 at least 1 year later <i>The minimum interval (8 weeks) can be considered for adults with an immunocompromising condition, cochlear implant, or cerebrospinal fluid leak.</i> <i>Reminder: No additional doses are indicated at this age if PCV15 or PCV20 was administered at a younger age.</i>
Cerebrospinal fluid leak		
Chronic heart disease ^a		
Chronic liver disease		
Chronic lung disease ^b		
Chronic renal failure ^c		
Cigarette smoking		
Cochlear implant		
Congenital or acquired asplenia ^c		
Congenital or acquired immunodeficiency ^{c,d}		
Diabetes mellitus		
Generalized malignancy ^c		
HIV infection ^c		
Hodgkin disease ^c		
Iatrogenic immunosuppression ^{c,e}		
Leukemia ^c		
Lymphoma ^c		
Multiple myeloma ^c		
Nephrotic syndrome ^c		
Sickle cell disease/other hemoglobinopathies ^c		
Solid organ transplant ^c		

PCV15, 15-valent pneumococcal conjugate vaccine; PCV20, 20-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine

^aIncludes congestive heart failure and cardiomyopathies

^bIncludes chronic obstructive pulmonary disease, emphysema, and asthma

^cConsidered an immunocompromising condition

^dIncludes B-(humoral) or T-lymphocyte deficiency, complement deficiencies (particularly C1, C2, C3, and C4 deficiencies), and phagocytic disorders (excluding chronic granulomatous disease)

^eIncludes diseases requiring treatment with immunosuppressive drugs such as long-term systemic corticosteroids and radiation therapy

concluded that maternal Tdap vaccination prevented 91.4% of pertussis infections among infants in the first 2 months of life, before the first infant dose of diphtheria, tetanus, and pertussis (DtaP) vaccine is typically administered.⁵⁴

In 2021, 73.6% of pregnant people in NYC reported that their provider recommended Tdap vaccine during any prenatal care visit, and 66.3% reported receiving Tdap vaccine (unpublished data, PRAMS). See [ACIP's complete Tdap vaccination recommendations](#) for pregnancy and pertussis.

PRESCRIBE ANTIVIRALS FOR TREATMENT AND PROPHYLAXIS

Treatment

Treat people at higher risk of influenza complications (**Box 9**^{6,55}). Four antiviral medications are approved to treat influenza A and B.⁵⁵

- Oral oseltamivir for patients aged 2 weeks and older: Adverse events include nausea, vomiting, and headache. Off-label use of oseltamivir for treatment of influenza in infants aged younger than 14 days is recommended by the CDC and the American Academy of Pediatrics.
- Inhaled zanamivir for patients aged 7 years and older: Adverse events include risk of bronchospasm, sinusitis, and dizziness. Zanamivir is not recommended for people with underlying respiratory diseases such as asthma or chronic obstructive pulmonary disease and those with a history of allergy to lactose or milk protein.
- Intravenous peramivir for patients aged 6 months and older: The most common side effect is diarrhea.
- Oral baloxavir for patients aged 5 years and older: There were no adverse events that were more common than with placebo during clinical trials.

Prophylaxis

Use oseltamivir (ages 3 months and older), zanamivir (ages 5 years and older), or baloxavir (ages 5 years and older) for prophylaxis if⁵⁵

- the patient is at high risk of complications after they are exposed to influenza, and
- the vaccine is medically contraindicated or was administered within 2 weeks after exposure.

Baloxavir is the only single-dose influenza

medication approved by the FDA for postexposure prophylaxis.⁵⁵ If a child is aged younger than 3 months, use of oseltamivir for chemoprophylaxis is not recommended unless the situation is judged critical, because of limited data in this age group.⁵⁵ Prophylaxis with oseltamivir, zanamivir, or baloxavir is generally not recommended if it has been more than 48 hours since initial exposure to influenza.⁵⁵

Peramivir is not recommended for prophylaxis.⁵⁵ See package inserts for complete product safety information. Amantadine and rimantadine are not recommended for treatment or prophylaxis of currently circulating influenza A viruses because of high levels of drug resistance; these agents are ineffective against influenza B viruses.⁵⁵

Influenza antiviral medications may reduce the effectiveness of LAIV if given within the following intervals^{1,55}:

- Oseltamivir or zanamivir: 48 hours before to 2 weeks after LAIV;
- Peramivir: 5 days before to 2 weeks after LAIV;
- Baloxavir: 17 days before to 2 weeks after LAIV.

BOX 9. HIGH-RISK GROUPS WHO SHOULD RECEIVE ANTIVIRAL TREATMENT FOR INFLUENZA^{6,55}

- Children aged younger than 2 years
- Adults aged 65 years and older
- People with
 - asthma or chronic lung disease (eg, chronic obstructive pulmonary disease, cystic fibrosis)
 - heart disease (eg, congenital heart disease, congestive heart failure, coronary artery disease) or stroke
 - renal, hepatic, neurologic, hematologic, or metabolic disorders, including diabetes
 - immunosuppression, including that caused by medications or by HIV infection
 - morbid obesity (ie, body mass index ≥ 40)
- People who are pregnant or up to 2 weeks after the end of pregnancy
- People aged younger than 19 years receiving long-term aspirin- or salicylate-containing medications
- NonLatino Black, Latino, and American Indian or Alaska Native people^a
- Residents of nursing homes and other long-term care facilities

^aRisk is due to structural racism and health care access; see [Health Equity and Flu](#)

REPORTING, ALERTS, AND SURVEILLANCE

Reporting vaccinations

- Report all vaccinations administered to children aged 18 years or younger to the CIR within 2 weeks of administration as required by NYS Public Health Law Section 2168 and NYC Health Code Section 11.07. To register with or access the CIR, visit the [CIR webpage](#).
- For patients aged 19 years and older, physicians are strongly encouraged to report vaccines administered to the CIR with the patient's oral or written consent.
 - Encourage patients to consent by discussing the advantages of reporting, such as online access to vaccine records.
- Pharmacists and registered nurses **must** get oral or written consent from people aged 19 years and older and report administered vaccinations to the CIR, as per NYS Public Health Law Section 2168.
- Incorporate CIR consent into a general consent process.
- Collect and report vaccine recipients' characteristics, including race and ethnicity, to the CIR to support equitable vaccine distribution and access.

Use your electronic health record (EHR) system to report immunizations to the CIR. Contact cir_interop@health.nyc.gov with your facility address, contact information, and current EHR, or call the NYC Provider Access Line at 866-692-3641. Providers may be eligible to receive Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) incentive payments when using their EHR to report to the CIR. For more information, see [Overview of Meaningful Use and Immunization Reporting](#) and [MACRA](#).

Reporting influenza cases and deaths

Report nosocomial cases of even 1 laboratory confirmed case of influenza or clusters of 2 or more cases of influenza-like illness in Article 28 facilities by:

- calling the NYS Department of Health at 518-474-1142 or
- using the Nosocomial Outbreak Reporting Application on the [Health Commerce System](#) or
- completing a [NYS Healthcare Facility Infection Control \(Nosocomial\) Report](#) and faxing it to 518-402-5165.

Report deaths in children aged younger than 18 years that occurred from a clinically compatible illness in which there is a positive influenza test or from an unknown febrile respiratory illness by calling the NYC Provider Access Line at 866-692-3641.

Visit [Reporting Diseases and Conditions](#) for more information.

Updates, alerts, and surveillance

- Register for NYC Department of Health and Mental Hygiene (DOHMH) alerts through the [Health Alert Network](#) or by calling 866-692-3641.
- Regularly review the NYC DOHMH's [Weekly Influenza Surveillance Summary](#) for information about local influenza activity, flu vaccine recommendations, and vaccine supply.

SUMMARY

Hospitalizations and deaths occur every influenza season. Influenza and SARS-CoV-2 viruses will be circulating at the same time. Use every opportunity to administer flu vaccines to all eligible persons aged 6 months and older to reduce the burden of respiratory illnesses in the community and protect vulnerable populations at risk of severe illness. Follow safe vaccinating practices and use evidence-based strategies such as standing orders and reminder-recall systems to improve flu vaccination rates and eliminate inequities (**Box 10**). Coadminister routine vaccines, such as pneumococcal and Tdap vaccines, and COVID-19 vaccines with flu vaccines in children and adults.

BOX 10. FLU VACCINE REMINDERS

- 1. Order enough vaccine**, including enough preservative-free vaccine for pregnant persons and children aged younger than 3 years.^a See [Influenza Vaccine Availability Tracking System—IVATS](#) for information
 - If you are enrolled in the [Vaccines for Children Program](#), order flu vaccines now if you have not already done so through the [Citywide Immunization Registry \(CIR\)](#). See [Dear Colleague letter](#) for details
- 2. Ensure you have sufficient medical supplies**, including syringes, needles, and epinephrine pens, to vaccinate and administer anaphylaxis treatment
- 3. Store vaccines safely** to ensure full potency. See the [CDC Vaccine Storage and Handling Toolkit](#) and [Checklist for Safe Vaccine Storage and Handling](#)
- 4. Use your electronic health record (EHR) system** or CIR to identify and contact patients who need vaccination and to monitor vaccination coverage in your practice
- 5. Document vaccines** administered and other required information in the patient's record. Provide a [Vaccine Information Statement \(VIS\)](#) in the appropriate language, and record in the medical record the date the VIS was given and the VIS edition date
- 6. Report all immunizations administered to all patients using the CIR**
 - Providers must report all flu vaccine doses administered to people aged younger than 19 years to the CIR. Providers administering flu vaccines to adults should report all doses with oral or written consent from the patient. You can access up-to-date influenza coverage reports for your practice any time during influenza season. Contact cir@health.nyc.gov with your facility address, contact information, and current EHR, or call 347-396-2400
 - To inform vaccination quality improvement initiatives, facilities can use the CIR to generate practice-level vaccine coverage reports, identify unvaccinated patients, and access the CIR texting function for reminder and recall messages. Guides for these CIR tools are available at the bottom of the [Online Registry sign-in page](#)
- 7. Report adverse reactions to the federal Vaccine Adverse Event Reporting System (VAERS)**, [online](#) or by calling 800-822-7967.

See Resources for information on increasing vaccination coverage in your practice

^aNew York State public health law prohibits the administration of vaccines containing more than trace amounts of thimerosal to children aged younger than 3 years and people who know they are pregnant, though the New York State Department of Health emphasizes that pregnant people and children aged younger than 3 years should not wait for influenza vaccine that complies with this law, if thimerosal-free vaccine is unavailable.

RESOURCES FOR PROVIDERS

New York City (NYC) Department of Health and Mental Hygiene (DOHMH)

- Provider Access Line: 866-NYC-DOH1 (866-692-3641)
- Immunization Information for Providers: <https://www.nyc.gov/site/doh/providers/health-topics/immunization-information-for-healthcare-providers.page>
See section on Influenza and Pneumococcal Information
- Letter to Providers: 2023-2024 Seasonal Influenza Vaccination: <https://www.nyc.gov/assets/doh/downloads/pdf/flu/dear-colleague-2023-seasonal-flu-kick-off-letter.pdf>
- Weekly Influenza Surveillance Summary: <https://www1.nyc.gov/site/doh/providers/health-topics/flu-alerts.page>
- Citywide Immunization Registry: <https://www1.nyc.gov/site/doh/providers/reporting-and-services/citywide-immunization-registry-cir.page>
User guides can be found at <https://immunize.nyc.gov/provider-client/servlet/PC>
- NYCMED: <https://a816-healthpsi.nyc.gov/NYCMED/Account/Login>
- Health Alert Network: <https://www.nyc.gov/site/doh/providers/resources/health-alert-network.page>
Sign up at <https://a816-healthpsi.nyc.gov/NYCMED/Account/Login> or 866-692-3641
- E-mail questions to: nycflu@health.nyc.gov

Improving vaccination coverage

- NYC DOHMH. Vaccines for Children Program (VFC): <https://www1.nyc.gov/site/doh/providers/nyc-med-cir/vaccines-for-children-program.page>
- NYC DOHMH. NYC VFC Provider Requirements. Enrollment and Recertification: <https://www1.nyc.gov/site/doh/providers/nyc-med-cir/vaccines-for-children-requirements.page>
- NYC DOHMH. Adult Immunization Action Kit: <https://www1.nyc.gov/site/doh/providers/resources/public-health-action-kits-adult-immunization.page>
- NYC DOHMH. Influenza Coverage and Text Messaging Recall: <https://www1.nyc.gov/assets/doh/downloads/pdf/cir/cir-flu-coverage-and-custom-recall-texting-guide.pdf>
- Centers for Disease Control and Prevention (CDC). Use of Reminder and Recall by Vaccination Providers: <https://www.cdc.gov/mmwr/preview/mmwrhtml/00054628.htm>
- CDC. Influenza (Flu) Print Materials: <https://www.cdc.gov/flu/resource-center/freeresources/index.html>
Downloadable posters and patient handouts by audience in different formats and languages
- CDC. Use of Standing Orders Programs to Increase Adult Vaccination Rates: <https://www.cdc.gov/mmwr/preview/mmwrhtml/rr4901a2.htm>

RESOURCES FOR PROVIDERS *(continued)*

- CDC. The Adult Vaccine Assessment Tool: <https://www2.cdc.gov/nip/adultimmsched>
- New York State (NYS) Office of the Professions. Nonpatient Specific Standing Order and Protocol Guidelines: <https://www.op.nysed.gov/professions/nursing/non-patient-specific-standing-order-and-protocol-guidelines>
- Immunize.org. Standing Orders for Administering Influenza Vaccine to Adults: <https://www.immunize.org/catg.d/p3074.pdf>
- Immunize.org. Standing Orders Templates for Administering Vaccines: <http://www.immunize.org/standing-orders>
- Centers for Medicare and Medicaid Services (CMS). Influenza Vaccination Strategies: <https://innovation.cms.gov/files/x/pgp-flu-vaccination.pdf>

Building trust and vaccine confidence

- World Health Organization. Conversations to Build Trust in Vaccination: A Training Module for Health Workers: <https://www.cominit.com/global/content/conversations-build-trust-vaccination-training-module-health-workers>
- US Department of Health and Human Services. Think Cultural Health: <https://www.thinkculturalhealth.hhs.gov>
Free accredited online educational program (registration required)
- University of Washington Health Sciences Library and Harborview Medical Center. EthnoMed: <https://ethnomed.org>
Community cultural profiles and subjects related to ethnic groups; patient education materials in various languages
- CDC. What is Health Equity?: <https://www.cdc.gov/health-equity/whatis>
- CDC. Racism and Health: <https://www.cdc.gov/minority-health/racism-disparities/index.html>
- CDC. Influenza (Flu): Health Equity and Flu: <https://www.cdc.gov/flu/highrisk/disparities-racial-ethnic-minority-groups.html>
- NYC DOHMH. Resolution of the NYC Board of Health Declaring Racism a Public Health Crisis: <https://www1.nyc.gov/assets/doh/downloads/pdf/boh/racism-public-health-crisis-resolution.pdf>

COVID-19 vaccines

- NYC DOHMH. COVID-19 Vaccine Information for Providers: <https://www1.nyc.gov/site/doh/covid/covid-19-providers-vaccines.page>
- CDC. Use of COVID-19 Vaccines in the United States: Interim Clinical Considerations: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>
- CDC. COVID-19: People with Certain Medical Conditions: <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html>
- CDC. Guidance for Planning Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations: <https://www.cdc.gov/vaccines/hcp/admin/mass-clinic-activities/index.html>

Immunization recommendations

- CDC. Influenza (Flu). Information for Health Professionals: www.cdc.gov/flu/professionals
- CDC. Vaccine Administration: <https://www.cdc.gov/vaccines/hcp/admin/admin-protocols.html>
- Advisory Committee on Immunization Practices (ACIP). Immunization Schedules: <https://www.cdc.gov/vaccines/schedules>
- CDC. Pneumococcal Vaccination: Summary of Who and When to Vaccinate: <https://www.cdc.gov/vaccines/vpd/pneumo/hcp/who-when-to-vaccinate.html>
- CDC. Pneumococcal Vaccine Timing for Adults: <https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf>
- ACIP. Pneumococcal Vaccine Recommendations: <https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html>
- ACIP. DTaP/Tdap/Td Vaccine Recommendations: <https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/dtap.html>
- ACIP. Shared Clinical Decision-Making Recommendations: <https://www.cdc.gov/vaccines/acip/acip-scdm-faqs.html>
- Immunize.org. Vaccines. Influenza: <http://www.immunize.org/influenza>
- Immunize.org. Checklist for Safe Vaccine Storage and Handling: <https://www.immunize.org/catg.d/p3035.pdf>
- American College of Physicians. Adult Immunization: <https://www.acponline.org/clinical-information/clinical-resources-products/adult-immunization>
- American College of Obstetricians and Gynecologists. Immunization: <http://www.immunizationforwomen.org>
- New York State (NYS) Department of Health (DOH). Regulation for Prevention of Influenza Transmission by Healthcare and Residential Facility and Agency Personnel: http://www.health.ny.gov/diseases/communicable/influenza/seasonal/providers/prevention_of_influenza_transmission
- NYS DOH. New York State Law Prohibits the Administration of Vaccines Containing More Than Trace Amounts of Thimerosal to Children Less Than 3 Years of Age and Pregnant Women: https://www.health.ny.gov/prevention/immunization/providers/state_law_restricting_thimerosal_2008-04-23.htm

Reporting and documentation

- NYC DOHMH. Overview of Meaningful Use and Immunization Reporting: <https://www1.nyc.gov/site/doh/providers/reporting-and-services/cir-ehr-meaningfuluse.page>
- NYC DOHMH. Reporting Diseases and Conditions: <https://www1.nyc.gov/site/doh/providers/reporting-and-services/notifiable-diseases-and-conditions-reporting-central.page>
- NYS DOH. Communicable Disease Reporting: <https://www.health.ny.gov/professionals/diseases/reporting/communicable>

RESOURCES FOR PROVIDERS *(continued)*

- NYS DOH. Health Commerce System Nosocomial Outbreak Reporting Application: <https://commerce.health.state.ny.us>
- NYS DOH. Health Care Facility Infection Control (Nosocomial) Report: <https://www.health.ny.gov/forms/doh-4018.pdf>
- CDC. CMS Requirements: <https://www.cdc.gov/nhsn/cms/index.html>
- CMS. Medicare Access and CHIP Reauthorization Act of 2015 (MACRA): <https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Value-Based-Programs/MACRA-MIPS-and-APMs/MACRA-MIPS-and-APMs>
- National Adult and Influenza Immunization Summit. Influenza Vaccine Availability Tracking System (IVATS): <https://www.izsummitpartners.org/ivats>

Vaccine safety

- US Department of Health and Human Services. Vaccine Adverse Event Reporting System (VAERS): <https://vaers.hhs.gov/reportevent.html>
- CDC. Vaccine Information Statements: <https://www.cdc.gov/vaccines/hcp/vis/index.html>

- CDC. Vaccine Excipient Table: <https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf>
- CDC. Vaccine Storage and Handling Toolkit: <https://www.cdc.gov/vaccines/hcp/admin/storage/toolkit/index.html>
- CDC. Thimerosal and Vaccines: <https://www.cdc.gov/vaccinesafety/concerns/thimerosal/index.html>

Coding and billing information

- Immunize.org. Vaccinating Adults. A Step-by-Step Guide: <https://www.immunize.org/guide>
See Step 7B: How to Bill for Adult Immunizations
- CMS. Flu Shot: <https://www.cms.gov/flu-provider>
- CMS. Medicare Part D Vaccines: <https://www.cms.gov/outreach-and-education/medicare-learning-network-mln/mlnproducts/downloads/vaccines-part-d-fact-sheet-icn908764.pdf>

City Health Information archives:

<https://www1.nyc.gov/site/doh/providers/resources/city-health-information-chi.page>

RESOURCES FOR PATIENTS

General information

- National Foundation for Infectious Diseases. Flu (Influenza): <https://www.nfid.org/infectious-disease/flu-influenza>

Educational materials

- New York City (NYC) Department of Health and Mental Hygiene (DOHMH). Seasonal Flu (Influenza): <http://www.nyc.gov/flu>
Publications, brochures, and posters
- NYC DOHMH. Adult Immunization Action Kit: <https://www1.nyc.gov/site/doh/providers/resources/public-health-action-kits-adult-immunization.page>
- NYC DOHMH. Vaccinations and Pregnancy: <https://www1.nyc.gov/site/doh/health/publications/health-bulletin/health-bulletin-119.page>
- Immunize.org. Vaccine Information Statements (VIS): <https://www.immunize.org/vis>

Available in many languages

- Centers for Disease Control and Prevention (CDC). Influenza (Flu): Communication Resource Center: <https://www.cdc.gov/flu/resource-center/index.htm>

Flyers, posters, and brochures for the public, families, children, and high-risk groups

Vaccination locations

- NYC Vaccine Finder: <https://vaccinefinder.nyc.gov>
- NYC DOHMH. Immunization Clinics: <http://www1.nyc.gov/site/doh/services/immunization-clinics.page>
- NYC Health + Hospitals. Services: <https://www.nychealthandhospitals.org/services>
- NYC DOHMH. NYC HealthMap: <https://a816-healthpsi.nyc.gov/nychealthmap>
Searchable map of health services
- US Department of Health and Human Services. Find a Health Center: <https://findahealthcenter.hrsa.gov>

REFERENCES

1. Grohskopf LA, et al. *MMWR Recomm Rep*. 2023;72(No RR-2):1-25. doi:10.15585/mmwr.rr7202a1
2. Centers for Disease Control and Prevention (CDC). Updated September 22, 2023. Accessed September 28, 2023. <https://www.cdc.gov/flu/weekly>
3. New York City (NYC) Department of Health and Mental Hygiene (DOHMH). Updated May 20, 2023. Accessed September 28, 2023. <https://www.nyc.gov/site/doh/providers/health-topics/flu-alerts.page>
4. CDC. Updated January 25, 2023. Accessed August 29, 2023. <https://www.cdc.gov/flu/about/burden-averted/2021-2022.htm>
5. Olsen SJ, et al. *MMWR Morb Mortal Wkly Rep*. 2021;70(29):1013-1019. doi:10.15585/mmwr.mm7029a1
6. CDC. Reviewed August 25, 2023. Accessed August 29, 2023. <https://www.cdc.gov/flu/highrisk/index.htm>
7. United States (US) Department of Health and Human Services. Accessed August 29, 2023. <https://health.gov/healthypeople/objectives-and-data/browse-objectives/vaccination>
8. NYC Law Department. June 28, 2018. Accessed August 29, 2023. <https://www1.nyc.gov/site/law/news/013-18/statements-corporation-counsel-chief-appeals-richard-dearing-health-commissioner-dr>
9. Scharff DP, et al. *J Health Care Poor Underserved*. 2010;21(3):879-897. doi:10.1353/hpu.0.0323

REFERENCES (continued)

10. López-Cevallos DF, et al. *J Rural Health*. 2014;30(4):344-351. doi:10.1111/jrh.12063
11. Simonds VW, et al. *J Gen Intern Med*. 2014;29(3):500-506. doi:10.1007/s11606-013-2578-y
12. Pacheco CM, et al. *Am J Public Health*. 2013;103(12):2152-2159. doi:10.2105/AJPH.2013.301480
13. Freimuth VS, et al. *Soc Sci Med*. 2017;193:70-79. doi:10.1016/j.socscimed.2017.10.001
14. Quinn SC, et al. *Vaccine*. 2016;35(8):1167-1174. doi:10.1016/j.vaccine.2016.12.046
15. Armstrong K, et al. *Am J Pub Health*. 2007;97(7):1283-1289. doi:10.2105/AJPH.2005.080762
16. Corbie-Smith G, et al. *Arch Intern Med*. 2002;162(21):2458-2463. doi:10.1001/archinte.162.21.2458
17. Jaiswal J, Halkitis PN. *Behav Med*. 2019;45(2):79-85. doi:10.1080/08964289.2019.1619511
18. Mersha TB, Beck AF. *Hum Genomics*. 2020;14(1):37. doi:10.1186/s40246-020-00284-2
19. Benedict KM, et al. *Vaccine*. 2017;35(9):1353-1361. doi:10.1016/j.vaccine.2016.04.061
20. Imburgia TM, et al. *Vaccine*. 2017;35(18):2338-2342. doi:10.1016/j.vaccine.2017.03.060
21. Quinn SC, Andrasik MP. *N Engl J Med*. 2021;385(2):97-100. doi:10.1056/NEJMp2103104
22. CDC. Reviewed June 16, 2023. Accessed August 30, 2023. <https://www.cdc.gov/flu/prevent/misconceptions.htm>
23. CDC. Reviewed November 21, 2022. Accessed August 30, 2023. <https://www.cdc.gov/flu/season/faq-flu-season-2022-2023.htm>
24. CDC. Reviewed September 30, 2021. Accessed August 30, 2023. <https://www.cdc.gov/vaccinesafety/vaccines/flu-vaccine.html>
25. CDC. Updated August 25, 2022. Accessed August 30, 2023. <https://www.cdc.gov/flu/prevent/nasalspray.htm>
26. CDC. Updated April 2, 2020. Accessed August 30, 2023. <http://www.cdc.gov/vaccines/vac-gen/side-effects.htm>
27. CDC. Reviewed August 25, 2020. Accessed August 30, 2023. <https://www.cdc.gov/vaccinesafety/concerns/thimerosal/index.html>
28. New York State (NYS) Education Department. Accessed August 30, 2023. <https://www.op.nysed.gov/professions/pharmacist/frequently-asked-questions/administration-of-immunizations>
29. US Department of Health and Human Services. *Federal Register*. 2020;85(164):52136-52141. <https://www.govinfo.gov/content/pkg/FR-2020-08-24/pdf/2020-18542.pdf>
30. NYS Department of Health (DOH). August 8, 2023. Accessed August 30, 2023. https://www.health.ny.gov/press/releases/2023/2023-08-08_rsv.htm
31. NYS DOH. Updated May 2023. Accessed August 30, 2023. http://www.health.ny.gov/diseases/communicable/influenza/seasonal/providers/prevention_of_influenza_transmission
32. Langdon-Embry M, et al. *MMWR Morb Mortal Wkly Rep*. 2020;69(30):999-1001. doi:10.15585/mmwr.mm6930a3
33. National Vaccine Advisory Committee (NVAC). *Public Health Rep*. 2014;129(2):115-123. doi:10.1177/003335491412900203
34. NYS DOH. Revised August 2023. Accessed September 18, 2023. https://www.health.ny.gov/prevention/immunization/laws_regs.htm
35. NVAC. *Pediatrics*. 2003;112(4):958-963. doi:10.1542/peds.112.4.958
36. Zaman K, et al. *N Engl J Med*. 2008;359(15):1555-1564. doi:10.1056/NEJMoa0708630
37. American College of Obstetricians and Gynecologists (ACOG). *Obstet Gynecol*. 2018;131(4):e109-e114. doi:10.1097/AOG.0000000000002588
38. Martin A, et al. *Matern Child Health J*. 2013;17(7):1325-1331. doi:10.1007/s10995-012-1135-3
39. Naleway AL, et al. *Vaccine*. 2014;32(26):3122-3127. doi:10.1016/j.vaccine.2014.04.021
40. Mertz D, et al. *BMC Infect Dis*. 2019;19(1):683. doi:10.1186/s12879-019-4318-3
41. CDC. Updated December 12, 2019. Accessed August 30, 2023. <https://www.cdc.gov/vaccines/pregnancy/hcp-toolkit/flu-vaccine-pregnancy.html>
42. CDC. Reviewed November 3, 2022. Accessed September 18, 2023. <https://www.cdc.gov/flu/prevent/vaccine-selection.htm>
43. CDC. Updated August 18, 2021. Accessed September 1, 2023. <https://www.cdc.gov/vaccines/pubs/pinkbook/genrec.html#print>
44. US Food and Drug Administration (FDA). September 11, 2023. Accessed September 18, 2023. <https://www.fda.gov/news-events/press-announcements/fda-takes-action-updated-mrna-covid-19-vaccines-better-protect-against-currently-circulating>
45. CDC. Updated May 18, 2022. Accessed September 5, 2023. <http://www.cdc.gov/pneumococcal/about/symptoms-complications.html>
46. CDC. Reviewed February 13, 2023. Accessed September 5, 2023. <https://www.cdc.gov/vaccines/vpd/pneumo/hcp/who-when-to-vaccinate.html>
47. Kobayashi M. June 22, 2023. Accessed September 5, 2023. <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-06-21-23/04-Pneumococcal-Kobayashi-508.pdf>
48. Kobayashi M, et al. *MMWR Recomm Rep*. 2023;72(No. RR-3):1-39. doi:10.15585/mmwr.rr7203a1
49. Melgar M, et al. *MMWR Morb Mortal Wkly Rep*. 2023;72(29):793-801. doi:10.15585/mmwr.mm7229a4
50. US FDA. August 21, 2023. Accessed September 26, 2023. <https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants>
51. CDC. September 22, 2023. Accessed September 23, 2023. <https://www.cdc.gov/media/releases/2023/p0922-RSV-maternal-vaccine.html>
52. Jones JM, et al. *MMWR Morb Mortal Wkly Rep*. 2023;72(34):920-925. doi:10.15585/mmwr.mm7234a4
53. Winter K, et al. *Clin Infect Dis*. 2015;61(7):1099-1106. doi:10.1093/cid/civ472
54. Baxter R, et al. *Pediatrics*. 2017;139(5):e20164091. doi:10.1542/peds.2016-4091
55. CDC. Reviewed September 9, 2022. Accessed September 6, 2023. <https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm>

City Health Information



42-09 28th Street, Long Island City, NY 11101

Eric Adams
Mayor

Ashwin Vasani, MD, PhD
Commissioner of Health and Mental Hygiene

Division of Disease Control
Celia Quinn, MD, MPH, Deputy Commissioner

Bureau of Immunization
Bindy L. Crouch, MD, MPH, Assistant Commissioner
Lih-Fan Chang, MD, MPH, Healthcare Facilities Lead

Division of Epidemiology
Gretchen Van Wye, MA, PhD, Acting Deputy Commissioner

Bureau of Public Health Training and Information Dissemination
Calaine Hemans-Henry, MPH, Assistant Commissioner
Joanna Osolnik, MPH, CHES, Senior Director, Office of Information Dissemination
Sandhya George, Director, Scientific Education Unit
Liz Selkove, Medical Editor, Scientific Education Unit
Peggy Millstone, Medical Editorial Consultant, Scientific Education Unit

Copyright ©2023 the New York City Department of Health and Mental Hygiene
E-mail *City Health Information* at askCHI@health.nyc.gov

New York City Department of Health and Mental Hygiene. Influenza prevention and control, 2023-2024. *City Health Information*. 2023;42(3):32-48.

ASK CHI

Have questions or comments
about influenza?

Email

AskCHI@health.nyc.gov

CONTINUING MEDICAL EDUCATION ACTIVITY

Instructions

1. Open the CME activity: <https://bit.ly/3EWySfm>.
2. Click on "Enroll" button.
3. Log in to the CME portal.
If this is your first time logging into the CME portal, you will need to create a user ID and password. To set this up, click on "Existing Account (Non-NYC Health + Hospitals User)." Then click on "Create one now!" or use this link to go directly to "Create a Profile": <https://bit.ly/3ROacut>
4. Follow the instructions to complete pre-test, view material, and complete post-test and evaluation. To receive CME credit, you must score at least 80% on the post-test and answer all evaluation questions.
5. Click "Print Session Certificate" to claim your credit and access the certificate.

CME accreditation statement for joint providership

New York City (NYC) Health + Hospitals is accredited by The Medical Society of the State of New York (MSSNY) to provide continuing medical education for physicians. This activity has been planned and implemented in accordance with the Accreditation Requirements and Policies of the MSSNY through the joint providership of NYC Health + Hospitals and the NYC Department of Health and Mental Hygiene. NYC Health + Hospitals designates this continuing medical education activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Financial disclosure and conflict of interest statement

Participating faculty members and planners have no relevant financial relationships to disclose.

Time to complete

This activity will take approximately 60 minutes to complete.